Evidence map›Paper›PMID 40928439›Full record

ArticleJACC. Case reports2025

Improved Cardiac Structure and Ventricular-Arterial Coupling After Baroreflex Activation Therapy.

Faysal Alhasan, Mark Hoffmann, Melissa Wendell, Renee Kursel, David Lewandowski, German Larrain, Ravi Dhingra

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Baroreflex Activation Therapy Invasive Hemodynamic "Reverse Ramp" Titration.Journal of the Society for Cardiovascular Angiography & Interventions · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Faysal AlhasanCardiovascular Division, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Mark HoffmannCardiovascular Division, Aspirus Health, Wausau, Wisconsin, USA.
Melissa WendellCardiovascular Division, Aspirus Health, Wausau, Wisconsin, USA.
Renee KurselCardiovascular Division, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
David LewandowskiCardiovascular Division, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
German LarrainCardiovascular Division, Aspirus Health, Wausau, Wisconsin, USA.
Ravi DhingraCardiovascular Division, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Electronic address: rdhingra@mcw.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Baroreflex activation therapy (BAT) improves functional status, quality of life, and exercise capacity in patients with heart failure with reduced ejection fraction; however, its direct effects on reversing adverse cardiac remodeling as assessed by improvements in cardiac structure, function, and coupling with the arterial system remain unclear. We present 2 cases of patients who initially presented with decompensated heart failure, and despite initial medical therapy and continued outpatient follow-up, were unable to tolerate full escalation of guideline-directed medical therapy. The patients remained symptomatic, with high biomarker levels, poor functional capacity, severe heart failure symptoms, and objectively had decreased stroke volume, low left ventricular ejection fraction, and high left ventricular mass. However, soon after implantation of BAT, not only did their heart failure symptoms and hemodynamics improve, but they were able to tolerate further escalation of medical therapy. After BAT, there was evidence of reverse cardiac remodeling, with improvement in biomarkers, left ventricular ejection fraction, contractility, and ventricular-arterial coupling.

Indexed as

baroreflexheart failuresystolicventricular remodeling

Identifiers

PMID40928439
PMCPMC12793882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.